MindMed has issued 24.95 million units at a unit price of CAD$0.53.
Psychedelics
Dr. Gabor Maté joins Numinus as Member of the Clinical Advisory Council
Maté will collaborate with the Numinus team in an advisory capacity and facilitate connections within the mental health community.
Champignon Appoints Dr. Bill Wilkerson to Board of Directors
Champignon Brands' new Director has extensive mental health credentials.
Mota Ventures Talks Strategy: Mushrooms and CBD
Mota Ventures is in the process of acquiring psychedelics manufacturer, Verrian.
Dr. Evan Wood, recognized leader in the field of substance use research and treatment, joins Numinus as Chief Medical Officer
Numinus names a new Chief Medical Officer.
Numinus Takes Off On Initial Day Of Trading
Numinus Wellness is a new psychedelics stock that is up over 300% on its initial day of trading.